State of New Product Development (As of October 23, 2026)

- If the product is being developed in multiple countries, including the US, "Global" is indicated in "Region/Country".
- When "Region/Country" is "Global", the most advanced stage of development among all regions/countries is indicated.
- If the "Stage" is filed and after, "Region/Country" is, in principle, Japan, the US, Europe, China, and Asia (excluding Japan and China). And not all region/countries are listed.
- ○ in “Changes” indicates changes from the previous announcement (as of July 24, 2026).

Central nervous system

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
ND0612 (Levodopa/Carbidopa)	Continuous SC pump	Parkinson's disease	Global	Phase 3		In-house
			US	Filed		
MT-0551 Uplizna (Inebilizumab)	Humanized anti-CD19 monoclonal antibody	Myasthenia gravis	Japan	Approved (Sep 2026)	○	Licensed from Amgen (US) and co-developed
MT-3921 (Unasnemab)	Anti-RGMa antibody	Spinal cord injury	Global	Phase 2		Co-discovered with Osaka University (Japan)
		HTLV-1 associated myelopathy	Japan	Phase 1		

Immuno-inflammation

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
MT-0551 Uplizna (Inebilizumab)	Humanized anti-CD19 monoclonal antibody	IgG4-related disease	Asia	Filed (Sep 2026)	○	Licensed from Amgen (US) and co-developed
		Systemic sclerosis	Japan	Phase 3		Licensed from Amgen (US)
MT-7117 (Dersimelagon)	Selective melanocortin 1 receptor agonist	Erythropoietic protoporphyria, X-Linked protoporphyria	Global	Phase 3		Transferred to LEO Pharma (Denmark)
			US	Filed (Jun 2026)	○	
		Systemic sclerosis	Global	Phase 2		
MT-2990	Fully human anti-interleukin-33 (IL-33) monoclonal antibody	ANCA associated vasculitis	Japan	Phase 1	○	Licensed to Tolerance Bio (US)
MT-3534	Antibody	Autoimmune disease	Japan	Phase 1		Co-discovered with Pharma Foods International (Japan)

Oncology

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
MT-2111 (Loncastuximab tesirine)	Anti-CD19 antibody drug conjugate	Relapsed/Refractory diffuse large B-cell lymphoma (monotherapy)	Japan	Phase 1/2		Licensed from ADC Therapeutics (Switzerland)
		Relapsed/Refractory diffuse large B-cell lymphoma (with rituximab)	Japan	Phase 3		Licensed from ADC Therapeutics (Switzerland) and co-developed (Global study ongoing)
MT-4561	BRD4 degraders	Advanced solid tumors	Global	Phase 1/2		In-house

Others

Development code Product name (Generic name)	Mechanism	Indications	Region/Country	Stage	Changes	Origin/Licensee
MT-1803	Combined vaccine	Prevention of pertussis, diphtheria, tetanus, poliomyelitis, Hib infection and hepatitis B	Japan	Phase 3	○	Co-developed with The Research Foundation for Microbial Diseases of Osaka University (Japan)